NASDAQ:KYMR Kymera Therapeutics (KYMR) Stock Price, News & Analysis $131.73 +3.61 (+2.82%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$131.58 -0.15 (-0.11%) As of 11/6/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Kymera Therapeutics Stock (NASDAQ:KYMR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kymera Therapeutics alerts:Sign Up Key Stats Today's Range$126.65▼$132.6850-Day Range$104.78▼$136.3052-Week Range$56.75▼$138.00Volume784,611 shsAverage Volume895,661 shsMarket Capitalization$11.25 billionP/E RatioN/ADividend YieldN/APrice Target$139.16Consensus RatingModerate Buy Company Overview Kymera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities. The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses. Kymera’s pipeline has included degraders directed at proteins such as IRAK4, STAT3, and STAT6, with candidates evaluated in clinical or preclinical studies depending on the program. The company continues to use its proprietary platform to identify and develop additional targeted protein degraders. Founded in 2016 and headquartered in the Boston-area biotechnology hub of Massachusetts, Kymera operates as a research-focused company and has advanced its programs through collaborations and clinical development activities. Its work is intended to support the development of medicines for patients in the United States and international markets, although the company’s programs remain centered on research and development rather than a broad portfolio of marketed products.AI Generated. May Contain Errors. Read More Kymera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreKYMR MarketRank™: 1.92619626926 of 5 starsKymera Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 659th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingModerate Buy Consensus RatingKymera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 23 buy ratings, 2 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Kymera Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageKymera Therapeutics has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kymera Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kymera Therapeutics are expected to decrease in the coming year, from ($3.88) to ($5.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kymera Therapeutics is -36.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kymera Therapeutics is -36.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKymera Therapeutics has a P/B Ratio of 6.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.13% of the float of Kymera Therapeutics has been sold short.Short Interest Ratio / Days to CoverKymera Therapeutics has a short interest ratio ("days to cover") of 9.96.Change versus previous monthShort interest in Kymera Therapeutics has recently decreased by 7.45%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKymera Therapeutics does not currently pay a dividend.Dividend GrowthKymera Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.40 News SentimentKymera Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Kymera Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 3 people have searched for KYMR on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows2 people have added Kymera Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Kymera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,158,324.00 in company stock.Percentage Held by Insiders15.98% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsKymera Therapeutics has minimal institutional ownership at this time.Read more about Kymera Therapeutics' insider trading history. Receive KYMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KYMR Stock News HeadlinesKymera Therapeutics (KYMR) Stock May Be Overvalued Following Positive KT 579 DataNovember 5 at 7:53 AM | finance.yahoo.comKymera Therapeutics (NASDAQ:KYMR) Reaches New 12-Month High on Analyst UpgradeNovember 5 at 1:21 AM | americanbankingnews.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 7 at 1:00 AM | Behind the Markets (Ad)Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock Now Rated "Moderate Buy" by Sell-Side BrokeragesNovember 4 at 3:17 AM | americanbankingnews.comKymera Therapeutics (NASDAQ:KYMR) Stock Gets Price Target Boost from BarclaysNovember 4 at 1:54 AM | americanbankingnews.comStock market today: Dow dips on election day; these biotech, insurance stocks clear entries (live coverage)November 3, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Thermo Fisher (TMO) and AbbVie (ABBV)November 3, 2026 | theglobeandmail.comKymera Therapeutics (KYMR) Gets a Buy from BTIGNovember 3, 2026 | theglobeandmail.comSee More Headlines KYMR Stock Analysis - Frequently Asked Questions How have KYMR shares performed this year? Kymera Therapeutics' stock was trading at $77.81 at the beginning of 2026. Since then, KYMR shares have increased by 69.3% and is now trading at $131.73. How were Kymera Therapeutics' earnings last quarter? Kymera Therapeutics, Inc. (NASDAQ:KYMR) posted its quarterly earnings data on Thursday, October, 29th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by $0.06. Kymera Therapeutics's revenue was up .0% on a year-over-year basis. Read the conference call transcript. When did Kymera Therapeutics IPO? Kymera Therapeutics (KYMR) raised $148 million in an IPO on Friday, August 21st 2020. The company issued 8,684,800 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO. Who are Kymera Therapeutics' major shareholders? Top institutional investors of Kymera Therapeutics include Fisher Asset Management LLC (0.38%), Pictet Asset Management Holding SA (0.36%), Candriam S.C.A. (0.22%) and Russell Investments Group Ltd. (0.09%). Insiders that own company stock include Bros Advisors Lp Baker, Venture Fund X LP Atlas, Nello Mainolfi, Bruce Booth, Bruce N Jacobs, Bvf Partners L P/Il, Jared Gollob, Ellen Chiniara, Brian Adams, Noah Goodman, Jeremy G Chadwick, Elena Ridloff and Joanna Horobin. View institutional ownership trends. How do I buy shares of Kymera Therapeutics? Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kymera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kymera Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Rocket Lab (RKLB), Archer Aviation (ACHR), Kratos Defense & Security Solutions (KTOS), Micron Technology (MU) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings10/29/2026Today11/07/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (18m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 KYMR's financial health is in the Green zone, according to TradeSmith. KYMR has been in this zone for over 18 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KYMR CIK1815442 Webwww.kymeratx.com Phone(857) 285-5314FaxN/AEmployees273Year Founded2017Price Target and Rating Average Price Target for Kymera Therapeutics$139.16 High Price Target$180.00 Low Price Target$100.00 Potential Upside/Downside+5.6%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage27 Analysts Profitability EPS (Trailing Twelve Months)($3.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$311.35 million Net Margins-285.33% Pretax Margin-341.78% Return on Equity-22.39% Return on Assets-20.48% Debt Debt-to-Equity RatioN/A Current Ratio11.13 Quick Ratio11.13 Sales & Book Value Annual Sales$39.21 million Price / Sales286.81 Cash FlowN/A Price / Cash FlowN/A Book Value$18.91 per share Price / Book6.97Miscellaneous Outstanding Shares85,370,000Free Float71,729,000Market Cap$11.25 billion OptionableOptionable Beta2.04 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:KYMR) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredOne Ticker Tied to a Coming 401k ChangeAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredTesla pays $0 in dividends. This new fund paid $452 in one month on $5,000.Tesla has never paid shareholders a dividend, not one cent. A new fund built on Tesla's stock takes a differen...Investors Alley | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
